<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002094</url>
  </required_header>
  <id_info>
    <org_study_id>117A</org_study_id>
    <secondary_id>M/3330/0007</secondary_id>
    <nct_id>NCT00002094</nct_id>
  </id_info>
  <brief_title>Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E</brief_title>
  <official_title>Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacia and Upjohn</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the time course of development of resistance to atevirdine mesylate ( U-87201E )&#xD;
      in patients with HIV isolates showing in vitro resistance to zidovudine ( AZT ). To determine&#xD;
      the genotype changes in HIV reverse transcriptase associated with in vitro AZT resistance to&#xD;
      U-87201E. To determine the genotype and phenotype effects of treatment with a&#xD;
      nondideoxynucleoside agent on the alterations of the HIV-1 population associated with in&#xD;
      vitro AZT resistance. To determine whether serial passage of patient pre-drug HIV isolates in&#xD;
      the presence of U-87201E will generate the resistant mutants that may subsequently emerge in&#xD;
      the patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atevirdine mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Enrollment on protocol RV-43 (AZT resistance study).&#xD;
&#xD;
          -  Development of a primary RV-43 study endpoint-opportunistic infection.&#xD;
&#xD;
          -  HIV isolate with an AZT IC50 &gt; 50 times that of the sensitive type strain.&#xD;
&#xD;
          -  Able to swallow tablets without difficulty.&#xD;
&#xD;
          -  Normal QTc interval on EKG.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Clinically significant hypersensitivity to piperazine type drugs (Antepar, Stelazine).&#xD;
&#xD;
          -  Severe uncontrollable diarrhea or vomiting or known malabsorption.&#xD;
&#xD;
          -  Symptomatic hyperlipidemia.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other experimental drugs.&#xD;
&#xD;
          -  AZT, ddI, ddC, foscarnet, immunomodulators or other agents with primary antiretroviral&#xD;
             activity (exemptions by principal investigator permitted).&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        History of clinically significant cardiovascular disease or nervous system or muscle&#xD;
        disease, including seizures, peripheral neuropathy, dementia, or motor dysfunction.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Experimental drugs within 4 weeks prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Natl Naval Med Ctr</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>208995000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 1993</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Virus Replication</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atevirdine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

